Free Trial

Kenvue (KVUE) Stock Price, News & Analysis

+0.19 (+1.04%)
(As of 07/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
17.55 million shs
Average Volume
19.36 million shs
Market Capitalization
$35.31 billion
P/E Ratio
Dividend Yield
Price Target

Kenvue MarketRank™ Stock Analysis

Analyst Rating
2.36 Rating Score
24.7% Upside
$23.00 Price Target
Short Interest
1.89% of Float Sold Short
Dividend Strength
Based on Four Factors
News Sentiment
0.75mentions of Kenvue in the last 14 days
Based on 12 Articles This Week
Insider Trading
Proj. Earnings Growth
From $1.13 to $1.26 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.78 out of 5 stars

Consumer Staples Sector

84th out of 134 stocks

Toilet Preparations Industry

6th out of 13 stocks

KVUE stock logo

About Kenvue Stock (NYSE:KVUE)

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.

KVUE Stock Price History

KVUE Stock News Headlines

Over the Counter drugs aisle in pharmacy
This Medical Giant's Stock Rebounds: A 15% Upside Is the Minimum (KVUE)
Johnson & Johnson reported a solid quarter for Q2 but issued mixed guidance. The critical detail is that sequential growth continues, and YOY growth is on tap.
This student turned $1,300 into $45,000 in just 4 Months!
With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.
Kenvue Inc. (NYSE:KVUE) Short Interest Up 28.7% in June
Kenvue (NYSE:KVUE) Price Target Cut to $20.00
3 Healthcare Stocks to Buy Now: June 2024
This student turned $1,300 into $45,000 in just 4 Months!
With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.
The 7 Best Under $20 Stocks to Buy in June 2024
Kenvue: A 4% Yield Worth Going Long
3 Dividend Aristocrats to Buy Today
Deep Dive Into Kenvue Stock: Analyst Perspectives (5 Ratings)
See More Headlines
Receive KVUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kenvue and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Ex-Dividend for 5/22 Dividend
Dividend Payable
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Toilet preparations
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
14 Analysts


Net Income
$1.66 billion
Pretax Margin


Sales & Book Value

Annual Sales
$15.44 billion
Cash Flow
$1.60 per share
Book Value
$5.85 per share


Outstanding Shares
Free Float
Market Cap
$35.31 billion
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Thibaut Mongon (Age 53)
    CEO & Director
    Comp: $4.79M
  • Mr. Paul Ruh (Age 56)
    Chief Financial Officer
    Comp: $2.33M
  • Ms. Meredith Stevens (Age 61)
    Chief Operations Officer
    Comp: $1.84M
  • Mr. Carlton Lawson (Age 55)
    Group President of EMEA & Latin America
    Comp: $2.28M
  • Ms. Ellie Bing Xie (Age 54)
    Group President of Asia Pacific
    Comp: $2.94M
  • Ms. Heather R. Howlett (Age 46)
    Chief Accounting Officer
  • Mr. Bernardo Tavares (Age 56)
    Chief Data & Technology Officer
  • Dr. Caroline Tillett (Age 52)
    Chief Scientific Officer
  • Ms. Tina Romani
    Head of Investor Relations
  • Mr. Matthew Orlando (Age 47)
    General Counsel

Should I Buy Kenvue Stock? KVUE Pros and Cons Explained


Here are some ways that investors could benefit from investing in Kenvue Inc.:

  • Kenvue Inc. reported a quarterly EPS of $0.28, exceeding analysts' consensus estimates by $0.03, indicating strong financial performance.
  • The company declared a quarterly dividend of $0.20 per share, offering investors a dividend yield of 4.34%, providing a steady income stream.
  • Several analysts have assigned a buy rating to Kenvue stock, suggesting positive sentiment and growth potential in the market.
  • Institutional investors and hedge funds own a significant portion (97.64%) of Kenvue's stock, indicating confidence from large financial entities.
  • Kenvue's current stock price is $18.52, potentially presenting a buying opportunity for investors looking for undervalued stocks.


Investors should be bearish about investing in Kenvue Inc. for these reasons:

  • Kenvue's quarterly revenue was down 24.9% on a year-over-year basis, indicating a decline in top-line growth.
  • The company's payout ratio is currently 102.56%, suggesting that it is paying out more in dividends than it is earning, which could be unsustainable in the long term.
  • One analyst has rated the stock with a sell rating, signaling potential concerns about the company's future performance.
  • Kenvue's debt-to-equity ratio of 0.66 may indicate higher financial leverage, which could pose risks during economic downturns.
  • The average target price for Kenvue stock is $23.09, which is higher than the current stock price, potentially indicating limited upside for investors.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, June 30, 2024. Please send any questions or comments about these Kenvue pros and cons to

KVUE Stock Analysis - Frequently Asked Questions

How have KVUE shares performed this year?

Kenvue's stock was trading at $21.53 at the beginning of 2024. Since then, KVUE shares have decreased by 14.4% and is now trading at $18.44.
View the best growth stocks for 2024 here

How were Kenvue's earnings last quarter?

Kenvue Inc. (NYSE:KVUE) announced its earnings results on Tuesday, May, 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.03. Kenvue's quarterly revenue was down 24.9% on a year-over-year basis.

When did Kenvue IPO?

Kenvue (KVUE) raised $3.3 billion in an initial public offering on Thursday, May 4th 2023. The company issued 151,200,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, Citigroup, Deutsche Bank Securities, BNP PARIBAS, HSBC, RBC Capital Markets and UBS Investment Bank acted as the underwriters for the IPO.

Who are Kenvue's major shareholders?

Kenvue's top institutional shareholders include DNB Asset Management AS (0.08%), Renaissance Capital LLC (0.05%), M&G Plc (0.04%) and Manning & Napier Advisors LLC (0.03%).
View institutional ownership trends

How do I buy shares of Kenvue?

Shares of KVUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:KVUE) was last updated on 7/18/2024 by Staff

From Our Partners